Promising anti-fibrotic approaches for future treatment of systemic sclerosis

Area of Science:

• Fibrosis research
• Molecular biology
• Drug discovery

Background:

• Aberrant fibroblast activation is a hallmark of systemic sclerosis (SSc).
• Pre-clinical studies have identified key molecular pathways driving SSc pathogenesis.
• Novel therapeutic strategies are needed for fibrotic disorders.

Purpose of the Study:

• To review recently identified molecular targets for anti-fibrotic therapies.
• To focus on targets relevant to systemic sclerosis (SSc) and other fibrotic conditions.
• To highlight drugs in clinical trials or approved for other indications.

Main Methods:

• Literature review of pre-clinical and clinical studies.
• Identification and summarization of molecular targets in fibrotic pathways.
• Analysis of drug development status for identified targets.

Main Results:

• Several key molecular pathways involved in fibroblast activation in SSc have been elucidated.
• Identified targets are amenable to therapeutic intervention with existing or investigational drugs.
• The review categorizes targets based on their stage of clinical development.

Conclusions:

• Novel anti-fibrotic approaches targeting specific molecular pathways show promise for SSc.
• Drug repurposing and development targeting these pathways could offer new treatment options.
• Further clinical evaluation is warranted for these targeted therapies in fibrotic diseases.